Dr. Laura Cappelli discusses Immune Related Adverse Events (IRAEs) of checkpoint inhibitors. She explains their development, common occurrences, risk factors, and the importance of a multidisciplinary approach. Topics include monitoring strategies, treatment approaches, collaboration between rheumatology and oncology, and using corticosteroids as primary therapy.